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Abstract 31 
32 
Objective: 33 
Single-length saphenous vein continues to be the conduit of choice in infected-field critical 34 
limb ischemia (CLI).  However, half of these individuals have inadequate vein secondary to previous 35 
use or chronic venous disease.  We reviewed our outcomes of infected-field infrainguinal bypasses 36 
performed with cryopreserved homografts (CH), a widely-accepted alternative to autogenous vein 37 
in this setting. 38 
39 
Methods: 40 
This is a retrospective, institutional descriptive analysis of infected-field infrainguinal 41 
revascularizations between 2012-2015.  42 
43 
Results: 44 
Twenty-four operations were performed in the same number of patients for limb ischemia 45 
with signs of active infection.  The mean age of the cohort examined was 62.5 ± 14.4 (standard 46 
deviation) years.  Mean SVS risk score was 3.9 with a baseline Rutherford’s chronic ischemia score 47 
of 4.3 at presentation.  Emergent procedures constituted 29% of cases and the remainder were 48 
urgent.  The CH bypass captured was a reoperative procedure in all but one of the patients.  Culture 49 
positivity was present in 75% of cases with S. aureus (29%) the most commonly isolated organism. 50 
51 
30-day mortality and major adverse cardiovascular events were both 4%.  Amputation free52 
survival (AFS) was 75% at 30-days.  Similarly, 30-day reintervention was 38% with debridement 53 
(43%) and bleeding (29%) the most common indications. 54 
55 
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Average duration of follow-up was 27.9 ± 20.4 months (range 0.5 – 60.4).  Mean length of 56 
stay was 14.8 days.  Reinfection requiring an additional procedure or antibiotic regimen separate 57 
from the index antibiotic course was 13%.  Primary patency and AFS at 1-year was 50% and 58%, 58 
respectively.  Primary patency and AFS at 2-years was 38% and 52%, respectively.  Limb salvage at 59 
one and 2-years was 70% and 65%.  Fifteen (63%) patients required reintervention during the 60 
follow-up period with 40% of those subjects undergoing multiple procedures. 61 
62 
Conclusions: 63 
CHs remain a marginal salvage conduit in the setting of infection and no autogenous 64 
choices.  Therefore, clinicians should individualize usage of this high-cost product in highly selected 65 
patients only.    66 
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Introduction 67 
68 
Autogenous single-length vein continues to remain the gold standard conduit for lower 69 
extremity infected-field revascularizations for critical limb ischemia (CLI).1  However, up to 45% of 70 
patients who require bypass do not have adequate continuous vein secondary to chronic venous 71 
disease or previous vein harvest.2,3  Unfortunately, the use of alternative synthetic conduits such as 72 
PTFE (polytetrafluroethylene) puts the patient at increased risk for graft infection and limb loss.  73 
Therefore, cryopreserved autologous homografts (CHs) have become a popular alternative in the 74 
infected surgical field.  The purpose of this retrospective analysis was to define outcomes for 75 
contemporary use of CHs in infected fields with respect to patency and limb salvage.    76 
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Methods 77 
78 
After obtaining Indiana University Institutional Review Board (IRB) approval, a single-79 
center retrospective review was completed of all infected-field CHs implanted for infrainguinal 80 
arterial disease from 2012 to 2015.  All procedures were performed at one institution by a group of 81 
nine academic surgeons.  Patients not seen by a vascular surgeon in our system for 12-months were 82 
deemed lost to follow-up; for those, contact by phone was attempted.  83 
84 
Demographics captured included age, sex, disease severity, and relevant comorbidities.  85 
Presence of infection was defined as observation of cellulitis overlying a bypass graft or perigraft 86 
purulence/fluid/air on imaging.  Operative characteristics captured included location of 87 
proximal/distal anastomosis, muscle flap usage, and intraoperative cultures.  Post-operative 88 
management strategies queried included use of anticoagulation, antiplatelets, and antibiotics 89 
duration. 90 
91 
CHs implanted were kept on-site in a liquid nitrogen dewar.  These conduits were prepared 92 
per manufacturer’s instruction but not routinely seromatched to the host.  Based on availability and 93 
surgeon preference, the choice of cryopreserved vein or artery was made on a case-by-case basis.  94 
CHs were used as the first choice in infected fields during this time over rifampin soaked prosthetic 95 
and spliced autogenous vein if continuous vein was not available.  All infected fields were copiously 96 
irrigated with antibiotic and saline solution.  No antibiotic impregnated beads were implanted in 97 
our series.   98 
99 
After surgery, all patients maintained IV or PO antibiotic use depending on the clinical 100 
severity of infection.  In general, it was our practice to extend antibiotics to 4-weeks before a 101 
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decision on additional duration was made in the outpatient setting.  Post-operative imaging, 102 
vascular labs, and overall management was left to the discretion of the individual attending 103 
surgeon.  Most commonly, a post-operative wound check was scheduled two to four weeks after the 104 
index procedure.  Graft surveillance was scheduled for every three months for the first year 105 
followed by every six months thereafter.  After the second year of follow-up, patients were 106 
extended to annual visits if the bypass remained patent.     107 
108 
Events captured included one and 2-year primary patency by vascular labs or CTA, one and 109 
2-year amputation free survival (AFS), reinterventions, reinfection, anastomotic bleeding,110 
mortality, and major adverse cardiovascular events (MACE).  AFS was defined as freedom from all-111 
cause mortality or above-ankle amputation.  Reinfection was defined as any decline in clinical 112 
status secondary to a new or persistent infection resulting in escalation of antibiotics, drainage, or 113 
reoperation to revise the index bypass graft.  114 
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Results 115 
116 
From 2012 to 2015, 24 infrainguinal CH (33% vein) bypasses were performed secondary to 117 
an infected conduit (n=23) or native artery (n=1).  The mean age of our population was 62.5 ± 14.4 118 
years (Table 1).  The most common comorbidities included previous bypass (96%), HTN (92%), 119 
active smoking (58%), HLD (54%), CAD (42%), and DM (25%). 120 
121 
Indications 122 
123 
Twelve percent of the patients were referred acutely after initial evaluation by an outside 124 
vascular surgeon for definitive management.  Mean Rutherford’s chronic limb ischemia score and 125 
mean SVS risk score were 4.3 and 3.9, respectively.4,5  Emergent procedures (performed within 6 126 
hours of admission) constituted 29% of cases and the remainder were urgent (within 24 hours).    127 
All patients demonstrated signs of local infection on physical exam or imaging; however, only 8% 128 
were septic at the time of presentation.  All but one of the procedures were performed as a repeat 129 
bypass.  This exception was a male with a primary infection of the superficial femoral artery 130 
secondary to chronic IV drug use and accidental arterial injection.   131 
132 
Intra-operative 133 
134 
Most of the infections were located in the groin (66.7%).  All proximal sites of anastomosis 135 
were distal to the external iliac artery.  Distal targets were divided into tibioperoneal (17%), below-136 
knee (4%), and above-knee (79%) categories.  Three patients received an extranatomic bypass 137 
consisting of two obturator bypasses and a femoral to femoral bypass via a retrorectus tunnel.  138 
Upon exploration, 33% of the patients had a pseudoaneurysm at the presumed site of infection 139 
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(Table 2).  The majority (92%) of the infected conduits were unincorporated into the soft tissue.  140 
Frank purulence was noted in 46% of limbs.  Complete graft explantation was completed in 61%, 141 
and the remainder received a partial explant at the location of active infection.  Rotational muscle 142 
flaps were utilized in 46% of cases.  Seventy-five percent of cultures returned an identifiable 143 
organism (Table 3).   The most common isolated organisms were S. aureus (29%), P. aeruginosa 144 
(24%), and coagulase negative Staphylococcus (24%).  Eighteen percent of positive cultures further 145 
demonstrated extended spectrum antibiotic resistance. 146 
147 
Post-operative and 30-day Outcomes 148 
149 
After the index operation, 38% of patients received therapeutic anticoagulation while 88% 150 
received antiplatelet therapy (Table 4).  All subjects received either IV (92%) or PO antibiotics in 151 
the peri-operative period.  The average duration of antibiotic coverage after surgery was 4.6 weeks. 152 
30-day AFS was 75% with a mortality rate of 4%.  The lone death occurred in an individual153 
presenting with peri-graft fluid and sepsis.  Antibiotic sensitive S. aureus was isolated from 154 
cultures, but the patient continued to decline clinically resulting in multi-system organ failure and 155 
eventual withdrawal of care by the family.  One patient experienced stroke/MI, suffering from an 156 
NSTEMI several days post-operatively.  Three (13%) patients experienced anastomotic bleeding 157 
with two requiring takebacks for exploration.  Reintervention at 30-days was 38% (n=7) most 158 
commonly for further debridement (4/7) or bleeding (2/7).  Average length of stay was 14.8 days. 159 
160 
Overall Outcomes 161 
162 
Mean follow-up for our population was 27.9 ± 20.4 months (Table 5).  Primary patency in 163 
our population at one and 2-years was 50% and 38%.  AFS at one and 2-years was 58% (6 164 
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amputations, 5 deaths) and 50% (7 amputations, 7 deaths).  Limb salvage at one and 2-years was 165 
70% and 65%, respectively.  Reintervention rate during follow-up was 63% with 40% of these 166 
patients requiring repeat bypass.  The most common cause of reintervention was for stenosis or 167 
occlusion; one third of reinterventions were for debridement or drainage.  There were no 168 
additional episodes of anastomotic bleeding during long-term follow-up compared to the three 169 
observed within 30-days.  Thirteen percent of patients had reinfection of the implanted CH.  Seven 170 
patients (29%) required major amputation (3 BKA, 4 AKA) during follow-up.  More than half, 54% 171 
of all treated patients died during the follow-up period (Figure 1).  Of these 11 deaths, 4 were from 172 
unknown causes outside of our hospital system.  The remainder of deaths occurred secondary to 173 
lung cancer (n=1), hepatic failure (1), pulmonary embolism (1), renal failure (2), and sepsis (2).      174 
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Discussion 175 
176 
The optimal management strategy for an infected lower extremity bypass graft or artery 177 
would be complete excision and in-line reconstruction with continuous autogenous vein.  178 
Unfortunately, availability of suitable vein having adequate caliber and length is lacking in many 179 
vascular patients with a previous history of bypass.6  In our cause, this was 96% of the population 180 
studied.  As such, we routinely employ the use of CHs if the operation involves a potentially infected 181 
field.  However, we do not routinely implant CHs for sterile-field bypasses given their dismal 182 
patency and limb salvage rates.7-10  183 
184 
CHs are harvested from multi-organ donors and preserved in dimethyl sulfoxide (DMSO) 185 
before being frozen in liquid nitrogen (-196°C) for storage.11  Additionally, each CH vendor employs186 
a unique preservation process to decrease antigenicity.  The complex harvest and preservation 187 
process does incur a significant financial burden to the patient when this conduit is selected for 188 
bypass.12  When needed, grafts are thawed to room temperature and individually modified by the 189 
surgeon.  After pressurization, the endothelial layer is slowly effaced and the tunica media 190 
infiltrated by leukocytes resulting in chronic fibrosis.13  This smoldering inflammatory response 191 
likely has a large role in late graft failure characterized by intense fibroplasia.14 192 
193 
CHs seem to be more resistant to infection than prosthetic materials through an unclear 194 
mechanism.  This effect has been postulated to be related to the presence of the conduit 195 
extracellular matrix allowing for the increased transfer of leukocytes and antibiotics into the 196 
perigraft space.15  Alternatively, it may be related to vendor-unique methods of tissue processing 197 
including the storage of grafts in the presence of antibiotics.16 198 
199 
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We report one and 2-year patencies of 50% and 38% corresponding to limb salvage rates of 200 
70% and 65%.  AFS during the same time periods were 58% and 52%.  Seven patients required 201 
amputation of the ischemic limb during the follow-up phase; however, amputation risk was 202 
frontloaded as all but one of the subjects lost their limb within 21 days of the index operation.  This 203 
data clearly suggests a danger period for limb loss in the perioperative phase of infected-field 204 
repeat bypasses.   205 
206 
Surprisingly, robust contemporary series describing CH conduits in infected fields have 207 
been few and small.10,17   Brown et al. reviewed their experience with CHs in infected fields which 208 
included peripheral, but also, carotid and visceral non-aortic reconstructions.  Their published 209 
experience described 39 total cases with a mean follow-up of 18 months.  Mortality at 30-days was 210 
2.6%.  Interestingly, graft reinfection did not occur in their population in contrast to our observed 211 
rate of 13%.  Unfortunately, their 1-year patency was not published.7  The largest series of 212 
cryopreserved vein bypasses was reported in 2003 of 240 consecutive cases in both clean and 213 
infected fields.  The majority (89%) were performed for rest pain or tissue loss.  The percentage of 214 
infected limbs were not published.  The authors did note an overall 30% 1-year primary patency 215 
and 80% limb salvage for all comers.8   216 
217 
We found a high reintervention rate of 63% in our study.  Twenty-eight additional 218 
reinterventions following the index procedure were documented in our 24 patients.  The most 219 
common indication was for stenosis, occlusion, or necrotizing soft tissue requiring a combination of 220 
angioplasty, thrombectomy, redo bypass, and debridement.  It seems apparent that the index 221 
bypass for this indication cannot be considered the final and definitive operation.  Therefore, before 222 
selecting the patient for limb salvage or primary amputation, it is imperative to disclose the risk of 223 
prolonged hospitalization and additional interventions.  Based on our experience, we have adopted 224 
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the use of cryopreserved homografts in infected fields with concurrent placement of a muscle flap 225 
when possible for the sole purpose of limb salvage.  After clearance of the infection, consideration 226 
should be made into reoperation with an alternative conduit to improve long-term outcomes.   227 
228 
Unfortunately, the retrospective nature of this study makes it impossible to be sure all 229 
adverse events were tracked and captured.  As many patients were referred to us from outside 230 
vascular surgeons and hospital systems – their follow-up often occurred external to our records.  231 
Regardless, the limited adverse events abstracted in this study illustrates well the poor prognosis of 232 
this population.  Another potential confounder present is inherent to a group practice, where 233 
multiple vascular surgeons perform operations per their expertise, often on the same patient.  Thus, 234 
standard protocol and procedure were lacking. 235 
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Conclusion 236 
237 
CHs are an accepted alternative to continuous autogenous vein for redo bypasses in the 238 
setting of an infected field.  However, the surgeon should be aware of the increased incidence of 239 
amputation, death, and reintervention prior to offering CH limb salvage for this difficult population. 240 
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Legends 
Table 1: Comorbidities 
Table 2: Operative characteristics 
Table 3: Culture results 
Table 4: Peri-operative management and results 
Table 5: Extended outcomes 
Figure 1: Kaplan-Meier analysis for AFS over time for patients receiving cryopreserved homografts 
in an infected surgical field.  The inputs displayed are all-cause mortality and major (above-ankle) 
amputation. 
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Comorbidity Incidence
HTN 92%
Active Smoker 58%
HLD 54%
CAD 42%
Obesity 33%
DM 25%
CRI (Cr > 1.5) 21%
CVD 17%
Arrhythmia 17%
HD 13%
COPD 8%
Rutherford’s Ischemia Score 4.3 ± 0.6
SVS Risk Score 3.9 ± 2.1
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Operative Characteristics Incidence
Emergent 29%
Septic 8%
Loss of Incorporation 92%
PSA 33%
Purulence 46%
Wound Culture Positive 75%
Muscle Flap 46%
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Patient # Graft Material Culture Results ESBL/MRSA
1 Synthetic S. aureus, S. marascens No
2 Synthetic Coagulase- Staph No
3 Synthetic Coagulase- Staph, P.
aeruginosa, Citrobacter
No
4 Synthetic P. aeruginosa No
5 Synthetic S. aureus Yes
6 Synthetic Klebsiella No
7 Vein P. aeruginosa Yes
8 Synthetic S. aureus, Enterococcus No
9 Synthetic Coagulase- Staphylococcus No
10 Synthetic S. aureus No
11 Synthetic Corynebacterium No
12 Native Artery P. aeruginosa No
13 Synthetic Corynebacterium No
14 Synthetic S. aureus Yes
15 Synthetic Coagulase- Staphylococcus No
16 Synthetic Enterococcus No
17 Synthetic Corynebacterium No
M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
Post-Operative Regimen Incidence
Antiplatelets 88%
Anticoagulation 38%
Antibiotics 100%
Antibiotic Duration 4.6 ± 2.2 Weeks
30-day Outcomes Incidence
MACE 4%
Major Amputation 21%
Mortality 4%
AFS 75%
Bleeding 13%
Reintervention 38%
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Long-Term Outcomes Incidence
Follow-up 27.9 ± 20.4 Months
LOS 14.8 ± 16.3 Days
Primary Patency 17.4 ± 18.2 Months
1-yr Primary Patency 50%
1-yr AFS 54%
2-yr Primary Patency 38%
2-yr AFS 52%
Reintervention Rate 63%
Reinfection 13%
Bleeding 13%
Major Amputation 29%
Death 54%
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